Abstract
Objectives: To develop nomograms predicting the incidence of castration-resistant prostate cancer (CRPC) and overall survival (OS) for de novo metastatic prostate cancer (PCa). Patients and Methods: Data from 449 patients with de novo metastatic PCa were retrospectively analysed. Patients were randomly divided into a training (n = 314, 70%) and a validation cohort (n = 135, 30%). Predictive factors were selected using a Cox proportional hazards model and were further used for building predictive models. The outcomes were incidence of CRPC and OS. Results: Predictive factors included: Gleason score (GS), intraductal carcinoma of the prostate (IDC-P), Eastern Cooperative Oncology Group status, and alkaline phosphatase, haemoglobin and prostate-specific antigen levels. IDC-P and GS were the strongest prognosticators for both the incidence of CRPC and OS. Nomograms for predicting CRPC and OS had an internal validated concordance index of 0.762 and 0.723, respectively. Based on the β coefficients of the final model, risk classification systems were constructed. For those with favourable, intermediate and poor prognosis, the median time to CRPC was 62.6, 28.0 and 13.0 months (P < 0.001), respectively; and the median OS was not reached, 55.0 and 33.0 months, respectively (P < 0.001). Conclusions: We developed two novel nomograms to predict the incidence of CRPC and OS for patients with de novo metastatic PCa. These tools may assist in physician decision-making and the designing of clinical trials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 994-1002 |
| Number of pages | 9 |
| Journal | BJU International |
| Volume | 122 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 1 2018 |
Fingerprint
Keywords
- #pcsm
- #ProstateCancer
- castration-resistant prostate cancer
- nomogram
- predictive model
- risk classification system
ASJC Scopus subject areas
- Urology
Cite this
Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer. / Zhao, Jinge; Sun, Guangxi; Liao, Banghua; Zhang, Xingming; Armstrong, Cameron M.; Yin, Xiaoxue; Liu, Jiandong; Chen, Junru; Yang, Yaojing; Zhao, Peng; Tang, Qidun; Wang, Zhenghao; Chen, Zhibin; Li, Xiong; Wei, Qiang; Li, Xiang; Chen, Ni; Gao, Allen C; Shen, Pengfei; Zeng, Hao.
In: BJU International, Vol. 122, No. 6, 01.12.2018, p. 994-1002.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer
AU - Zhao, Jinge
AU - Sun, Guangxi
AU - Liao, Banghua
AU - Zhang, Xingming
AU - Armstrong, Cameron M.
AU - Yin, Xiaoxue
AU - Liu, Jiandong
AU - Chen, Junru
AU - Yang, Yaojing
AU - Zhao, Peng
AU - Tang, Qidun
AU - Wang, Zhenghao
AU - Chen, Zhibin
AU - Li, Xiong
AU - Wei, Qiang
AU - Li, Xiang
AU - Chen, Ni
AU - Gao, Allen C
AU - Shen, Pengfei
AU - Zeng, Hao
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Objectives: To develop nomograms predicting the incidence of castration-resistant prostate cancer (CRPC) and overall survival (OS) for de novo metastatic prostate cancer (PCa). Patients and Methods: Data from 449 patients with de novo metastatic PCa were retrospectively analysed. Patients were randomly divided into a training (n = 314, 70%) and a validation cohort (n = 135, 30%). Predictive factors were selected using a Cox proportional hazards model and were further used for building predictive models. The outcomes were incidence of CRPC and OS. Results: Predictive factors included: Gleason score (GS), intraductal carcinoma of the prostate (IDC-P), Eastern Cooperative Oncology Group status, and alkaline phosphatase, haemoglobin and prostate-specific antigen levels. IDC-P and GS were the strongest prognosticators for both the incidence of CRPC and OS. Nomograms for predicting CRPC and OS had an internal validated concordance index of 0.762 and 0.723, respectively. Based on the β coefficients of the final model, risk classification systems were constructed. For those with favourable, intermediate and poor prognosis, the median time to CRPC was 62.6, 28.0 and 13.0 months (P < 0.001), respectively; and the median OS was not reached, 55.0 and 33.0 months, respectively (P < 0.001). Conclusions: We developed two novel nomograms to predict the incidence of CRPC and OS for patients with de novo metastatic PCa. These tools may assist in physician decision-making and the designing of clinical trials.
AB - Objectives: To develop nomograms predicting the incidence of castration-resistant prostate cancer (CRPC) and overall survival (OS) for de novo metastatic prostate cancer (PCa). Patients and Methods: Data from 449 patients with de novo metastatic PCa were retrospectively analysed. Patients were randomly divided into a training (n = 314, 70%) and a validation cohort (n = 135, 30%). Predictive factors were selected using a Cox proportional hazards model and were further used for building predictive models. The outcomes were incidence of CRPC and OS. Results: Predictive factors included: Gleason score (GS), intraductal carcinoma of the prostate (IDC-P), Eastern Cooperative Oncology Group status, and alkaline phosphatase, haemoglobin and prostate-specific antigen levels. IDC-P and GS were the strongest prognosticators for both the incidence of CRPC and OS. Nomograms for predicting CRPC and OS had an internal validated concordance index of 0.762 and 0.723, respectively. Based on the β coefficients of the final model, risk classification systems were constructed. For those with favourable, intermediate and poor prognosis, the median time to CRPC was 62.6, 28.0 and 13.0 months (P < 0.001), respectively; and the median OS was not reached, 55.0 and 33.0 months, respectively (P < 0.001). Conclusions: We developed two novel nomograms to predict the incidence of CRPC and OS for patients with de novo metastatic PCa. These tools may assist in physician decision-making and the designing of clinical trials.
KW - #pcsm
KW - #ProstateCancer
KW - castration-resistant prostate cancer
KW - nomogram
KW - predictive model
KW - risk classification system
UR - http://www.scopus.com/inward/record.url?scp=85056803113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056803113&partnerID=8YFLogxK
U2 - 10.1111/bju.14398
DO - 10.1111/bju.14398
M3 - Article
C2 - 29772102
AN - SCOPUS:85056803113
VL - 122
SP - 994
EP - 1002
JO - BJU International
JF - BJU International
SN - 1464-4096
IS - 6
ER -